isoxazoles has been researched along with cytochrome c-t in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
Authors | Studies |
---|---|
Beerheide, W; Boelsterli, UA; Latchoumycandane, C; Sattabongkot, J; Seah, QM; Tan, RC | 1 |
Azzolina, A; Cervello, M; Cusimano, A; D'Alessandro, N; Foderà , D; Lampiasi, N; Montalto, G | 1 |
Bushman, LR; Chen, P; Hail, N | 1 |
Gao, E; He, B; Koch, W; Lau, WB; Ma, XL; Pu, J; Shan, P; Wang, X; Wang, Y; Yuan, A | 1 |
Ahirwar, DK; Charan, M; Chatterjee, N; Das, S; Ganju, RK; Kaul, K; Mishra, S; Misri, S; Satoskar, AR; Varikuti, S | 1 |
5 other study(ies) available for isoxazoles and cytochrome c-t
Article | Year |
---|---|
Leflunomide or A77 1726 protect from acetaminophen-induced cell injury through inhibition of JNK-mediated mitochondrial permeability transition in immortalized human hepatocytes.
Topics: Acetaminophen; Aniline Compounds; Anthracenes; Antirheumatic Agents; Caspase 3; Cell Death; Cell Line; Crotonates; Cytochromes c; Dose-Response Relationship, Drug; Enzyme Activation; Glutathione; Hepatocytes; Humans; Hydroxybutyrates; Isoxazoles; JNK Mitogen-Activated Protein Kinases; Leflunomide; Mitochondria, Liver; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; Nitriles; Phosphorylation; Protein Carbonylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Toluidines | 2006 |
Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway.
Topics: Apoptosis; Blotting, Western; Butadienes; Carcinoma, Hepatocellular; Caspases; Cell Proliferation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Cytochromes c; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Flow Cytometry; Humans; Isoxazoles; Liver Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase Kinases; Nitriles; Phosphorylation; Pyrazoles; Sulfones; Time Factors; Tumor Cells, Cultured | 2007 |
Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for teriflunomide in prostate cancer chemoprevention.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Caspases; Cell Line, Transformed; Cytochromes c; Dose-Response Relationship, Drug; Epithelial Cells; Flow Cytometry; Humans; Immunoblotting; Isoxazoles; Leflunomide; Male; Membrane Potential, Mitochondrial; Mitochondria; Oxygen Consumption; Prostate; Prostatic Neoplasms; Reactive Oxygen Species; Time Factors; Tumor Cells, Cultured | 2010 |
Cardiomyocyte-expressed farnesoid-X-receptor is a novel apoptosis mediator and contributes to myocardial ischaemia/reperfusion injury.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspase 9; Cell Survival; Chenodeoxycholic Acid; Cyclosporine; Cytochromes c; Enzyme Inhibitors; Isoxazoles; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitochondria, Heart; Myocardial Reperfusion Injury; Myocytes, Cardiac; Pregnenediones; Proto-Oncogene Proteins c-bcl-2; Rats; Reactive Oxygen Species; Receptors, Cytoplasmic and Nuclear; RNA, Small Interfering | 2013 |
Macrophage migration inhibitory factor inhibition as a novel therapeutic approach against triple-negative breast cancer.
Topics: Animals; Apoptosis; Caspases; Cell Movement; Cell Survival; Cytochromes c; Disease Progression; Enzyme Activation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Inflammation; Intramolecular Oxidoreductases; Isoxazoles; Macrophage Migration-Inhibitory Factors; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Morpholines; Neoplasm Metastasis; Neoplasm Transplantation; Treatment Outcome; Triple Negative Breast Neoplasms; Wound Healing | 2020 |